The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...
In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...
TORK US on MSN4d
This is how Audi was born: the origin of its iconic four ringsThis is the origin of the Audi logo, a symbol full of globalization, a design available to any mortal, easy to reproduce by ...
AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top ...
DelveInsight's ROS1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...
AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback